Clinical trial · Interventional
Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance
A Pragmatic Randomised, Trial Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance (REaCT-TEMPO)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this randomized, pragmatic clinical trial is to evaluate an endocrine therapy dose-frequency escalation strategy and its effects on tolerability and compliance. Participants will be randomized to standard daily dosing of endocrine therapy or endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dose-frequency escalation administration of Endocrine therapy | Drug | — | UNRESOLVED |
| Standard of care administration of Endocrine therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard daily dosing of endocrine therapy
- description
- Standard daily dosing of endocrine therapy
- interventionNames
- Drug: Standard of care administration of Endocrine therapy
- type
- EXPERIMENTAL
- label
- Endocrine therapy dose-frequency escalation
- description
- Endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.
- interventionNames
- Drug: Dose-frequency escalation administration of Endocrine therapy
Primary outcomes (1)
- measure
- 1-year adherence with prescribed endocrine therapy
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with an early stage or locally advanced hormonal receptor positive breast cancer * Plan to receive endocrine therapy * Able to provide oral consent * Willing and able to complete questionnaires as per study protocol Exclusion Criteria: * Metastatic cancer * Adjuvant abemaciclib
References
Publications (0)
Data not yet available